Bristol Myers Squibb Reaches Licensing Deal with SystImmune for New Cancer Meds
- December 15, 2023
Bristol Myers Squibb (BMS) and SystImmune have entered into an agreement to jointly develop and commercialize the biopharmaceutical company’s bispecific antibody-drug conjugate (ADC) for treating certain types of lung and breast cancer.
ARTICLE TAGS
You must be logged in to access this content.